Component

RA-enriched Perilla frutescens extract

RA-enriched Perilla frutescens extract

4 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Caffeic acid, ferulic acid and trace m-coumaric acid were detected in urine after the perilla preparation.

    RA-enriched Perilla frutescens extract → Caffeic acid Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Indexed primary abstract; publisher-linked erratum exists but its body was inaccessible. Corrected numerical details beyond the abstract are not verified.; Publisher identifies an erratum linked to the original paper. Correction body inaccessible; scope not independently verified.
    experimental_model
    Same six-person study; urine collected to 48 h.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Rosmarinic acid collection; exact intervention and molecular form govern interpretation. · Rosmarinic acid
    plain_language
    Caffeic acid, ferulic acid and trace m-coumaric acid were detected in urine after the perilla preparation.
    primary_references
    Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens extract in humans. | https://pubmed.ncbi.nlm.nih.gov/15309457/ | https://doi.org/10.1007/s00394-004-0482-2
    primary_references
    Erratum: Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens extract in humans | https://link.springer.com/article/10.1007/s00394-004-0524-9
    source_locator
    Reviewed reference ra-human-degradation-products; RA-related urinary recovery was 6.3 ± 2.2% of dose. This is not a human absolute-bioavailability or intact-colon-delivery measurement.

    Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026) · lines 60–67

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Same six-person study; urine collected to 48 h. · Recorded from source · Recorded from source

    ### ra-human-degradation-products Caffeic acid, ferulic acid and trace m-coumaric acid were detected in urine after the perilla preparation. RA-related urinary recovery was 6.3 ± 2.2% of dose. This is not a human absolute-bioavailability or intact-colon-delivery measurement. Model and exposure: Same six-person study; urine collected to 48 h. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens extract in humans. | 2005 | https://pubmed.ncbi.nlm.nih.gov/15309457/ | https://doi.org/10.1007/s00394-004-0482-2 | Access: Indexed primary abstract; publisher-linked erratum exists but its body was inaccessible. Corrected numerical details beyond the abstract are not verified. Reference: Erratum: Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens extract in humans | 2005 | https://link.springer.com/article/10.1007/s00394-004-0524-9 | Access: Publisher identifies an erratum linked to the original paper. Correction body inaccessible; scope not independently verified.
    Complete structured claim and evidence

  2. Methylated RA appeared in human plasma and urine after perilla extract containing 200 mg RA.

    RA-enriched Perilla frutescens extract → O-Methylrosmarinic acid, site unresolved Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Indexed primary abstract; publisher-linked erratum exists but its body was inaccessible. Corrected numerical details beyond the abstract are not verified.; Publisher identifies an erratum linked to the original paper. Correction body inaccessible; scope not independently verified.
    experimental_model
    Six men; placebo crossover, 10-day interval; LC-MS.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Rosmarinic acid collection; exact intervention and molecular form govern interpretation. · Rosmarinic acid
    plain_language
    Methylated RA appeared in human plasma and urine after perilla extract containing 200 mg RA.
    primary_references
    Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens extract in humans. | https://pubmed.ncbi.nlm.nih.gov/15309457/ | https://doi.org/10.1007/s00394-004-0482-2
    primary_references
    Erratum: Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens extract in humans | https://link.springer.com/article/10.1007/s00394-004-0524-9
    source_locator
    Reviewed reference ra-human-methyl-metabolite; Methyl-RA plasma Tmax 2 h; conjugated species predominated. Erratum body not recovered.

    Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026) · lines 51–58

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Six men; placebo crossover, 10-day interval; LC-MS. · Recorded from source · Recorded from source

    ### ra-human-methyl-metabolite Methylated RA appeared in human plasma and urine after perilla extract containing 200 mg RA. Methyl-RA plasma Tmax 2 h; conjugated species predominated. Erratum body not recovered. Model and exposure: Six men; placebo crossover, 10-day interval; LC-MS. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens extract in humans. | 2005 | https://pubmed.ncbi.nlm.nih.gov/15309457/ | https://doi.org/10.1007/s00394-004-0482-2 | Access: Indexed primary abstract; publisher-linked erratum exists but its body was inaccessible. Corrected numerical details beyond the abstract are not verified. Reference: Erratum: Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens extract in humans | 2005 | https://link.springer.com/article/10.1007/s00394-004-0524-9 | Access: Publisher identifies an erratum linked to the original paper. Correction body inaccessible; scope not independently verified.
    Complete structured claim and evidence

  3. RA-enriched perilla extract improved selected symptom responder rates versus placebo.

    RA-enriched Perilla frutescens extract → Human seasonal rhinoconjunctivitis symptom response Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
    experimental_contrast
    {"intervention": "Enriched perilla regimen", "comparator": "Placebo", "endpoint": "RA-enriched perilla extract improved selected symptom responder rates versus placebo.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    29 mild-SAR patients, 21 days; reported RA-enriched 200-mg (n=10), 50-mg (n=9), placebo (n=10) groups.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Rosmarinic acid collection; exact intervention and molecular form govern interpretation. · Rosmarinic acid
    plain_language
    RA-enriched perilla extract improved selected symptom responder rates versus placebo.
    primary_references
    Extract of Perilla frutescens enriched for rosmarinic acid, a polyphenolic phytochemical, inhibits seasonal allergic rhinoconjunctivitis in humans. | https://pubmed.ncbi.nlm.nih.gov/14988517/ | https://doi.org/10.1177/153537020422900305
    source_locator
    Reviewed reference ra-perilla-allergy; Itchy nose, watery eyes, itchy eyes and total symptoms; not isolated RA or a demonstrated intracellular mediator.

    Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026) · lines 285–291

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · 29 mild-SAR patients, 21 days; reported RA-enriched 200-mg (n=10), 50-mg (n=9), placebo (n=10) groups. · Recorded from source · Recorded from source

    ### ra-perilla-allergy RA-enriched perilla extract improved selected symptom responder rates versus placebo. Itchy nose, watery eyes, itchy eyes and total symptoms; not isolated RA or a demonstrated intracellular mediator. Model and exposure: 29 mild-SAR patients, 21 days; reported RA-enriched 200-mg (n=10), 50-mg (n=9), placebo (n=10) groups. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Extract of Perilla frutescens enriched for rosmarinic acid, a polyphenolic phytochemical, inhibits seasonal allergic rhinoconjunctivitis in humans. | 2004 | https://pubmed.ncbi.nlm.nih.gov/14988517/ | https://doi.org/10.1177/153537020422900305 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
    Complete structured claim and evidence

  4. Active perilla-extract treatment reduced nasal-lavage neutrophil and eosinophil counts.

    RA-enriched Perilla frutescens extract → Human nasal lavage neutrophil/eosinophil counts Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
    experimental_contrast
    {"intervention": "Enriched perilla extract", "comparator": "Placebo", "endpoint": "Active perilla-extract treatment reduced nasal-lavage neutrophil and eosinophil counts.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    Same 29-patient, 21-day trial.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Rosmarinic acid collection; exact intervention and molecular form govern interpretation. · Rosmarinic acid
    plain_language
    Active perilla-extract treatment reduced nasal-lavage neutrophil and eosinophil counts.
    primary_references
    Extract of Perilla frutescens enriched for rosmarinic acid, a polyphenolic phytochemical, inhibits seasonal allergic rhinoconjunctivitis in humans. | https://pubmed.ncbi.nlm.nih.gov/14988517/ | https://doi.org/10.1177/153537020422900305
    source_locator
    Reviewed reference ra-perilla-nasal-cells; No adverse events or routine blood-test abnormalities were reported in this small trial. Oral administration did not directly bathe nasal tissue.

    Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026) · lines 293–299

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Same 29-patient, 21-day trial. · Recorded from source · Recorded from source

    ### ra-perilla-nasal-cells Active perilla-extract treatment reduced nasal-lavage neutrophil and eosinophil counts. No adverse events or routine blood-test abnormalities were reported in this small trial. Oral administration did not directly bathe nasal tissue. Model and exposure: Same 29-patient, 21-day trial. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Extract of Perilla frutescens enriched for rosmarinic acid, a polyphenolic phytochemical, inhibits seasonal allergic rhinoconjunctivitis in humans. | 2004 | https://pubmed.ncbi.nlm.nih.gov/14988517/ | https://doi.org/10.1177/153537020422900305 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.